Evidence map›Paper›PMID 41025537›Full record

ArticleInternational forum of allergy & rhinology2026

Sinonasal Sarcomas Management: An International Consensus Statement.

Alessandro Vinciguerra, Francesca Caspani, Marco Valentini, Anna Maria Camarda, Salvatore Provenzano, Eric W Wang, Cem Meço, Marco Ferrari, Pavol Surda, Semi Harrabi and 42 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in International forum of allergy & rhinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Comparative validation of current staging systems in sinonasal soft tissue sarcomas: a population-based analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  3. Article
  4. Sinonasal Sarcomas Management: An International Consensus Statement.International forum of allergy & rhinology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Alessandro VinciguerraDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, ASST Lariana, Como, Italy.
Francesca CaspaniHead and Neck Medical Oncology Department, ASST Lariana, Como, Italy.
Marco ValentiniDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, ASST Lariana, Como, Italy.
Anna Maria CamardaRadiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Salvatore ProvenzanoDepartment of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.ORCID https://orcid.org/0000-0003-0425-4692
Eric W WangDepartment of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-1180-5854
Cem MeçoDepartment of Otorhinolaryngology - Head and Neck Surgery, Ankara University Medical School, Ankara, Turkiye.
Marco FerrariSection of Otorhinolaryngology - Head and Neck Surgery, Department of Neuroscience (DNS), University of Padova, Padova, Italy.ORCID https://orcid.org/0000-0002-4023-0121
Pavol SurdaOtolaryngology, Guy's and St Thomas' Hospitals NHS Trust, London, UK.
Semi HarrabiHeidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Fernando Augusto Batista CamposDepartment of Medical Oncology, A.C.Camargo Cancer Center, São Paulo, Brazil.
Javier Martin BrotoMedical Oncology Department, Fundacion Jimenez Diaz University Hospital, University Hospital General De Villalba, Madrid, Spain.
B Ashleigh GuadagnoloDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pierina NavarriaDepartment of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Ali HosniRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Nadia HindiMedical Oncology Department, Fundacion Jimenez Diaz University Hospital, University Hospital General De Villalba, Madrid, Spain.
Antoine ItalianoFaculty of Medicine, University of Bordeaux, Bordeaux, France.
Daniel M TrifilettiDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA.
Bernd KasperSarcoma Unit, University of Heidelberg, Mannheim Cancer Center (MCC), Mannheim University Medical Center, Mannheim, Germany.
Benjamin VerillaudOtorhinolaryngology and Skull Base Center, AP-HP, Hôpital Lariboisière, Université De Paris, Paris, France.
Alberto SchreiberUnit of Otorhinolaryngology, Manerbio and Desenzano Hospitals, ASST Del Garda, Brescia, Italy.ORCID https://orcid.org/0000-0002-1580-3928
Paolo CastelnuovoDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, ASST Lariana, Como, Italy.
Piero NicolaiSection of Otorhinolaryngology - Head and Neck Surgery, Department of Neuroscience (DNS), University of Padova, Padova, Italy.
Iacopo DallanSkull Base and Rhino-orbital Surgery Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Matias ChaconDepartment of Medical Oncology, Alexander Fleming Cancer Institute, Buenos Aires, Argentina.
Shirley Y SuDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Juliette ThariatDepartment of Radiation Oncology, Centre François-Baclesse, Caen, France.
Claudia ValverdeDepartment of Medical Oncology, Vall D'hebron University Hospital, Barcelona, Spain.
Matt LechnerDivision of Surgery and Interventional Science and UCL Cancer Institute, London, UK.ORCID https://orcid.org/0000-0002-7123-0773
Jean Yves BlayMedical Oncology Department, Centre Leon Berard, Lyon, France.ORCID https://orcid.org/0000-0003-2893-7818
Maria Rosaria FioreRadiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Jean Anderson EloyDepartment of Otolaryngology, Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Mehdi BrahmiMedical Oncology Department, Centre Leon Berard, Lyon, France.
James N PalmerDepartment of Otorhinolaryngology, Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Victor Castro OlidenDepartment of Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
Daniela GretoAzienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit, Florence, Italy.
Iwona LugowskaMaria Sklodowska-Curie Institute of Oncology Warsaw, Warszawa, Poland.
Angelo Paolo Dei TosSurgical Pathology and Cytopathology Unit, Department of Medicine- DIMED, University of Padua School of Medicine, Padua, Italy.
Thibaut van ZeleDepartment of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.
Alkis J PsaltisDepartment of Otolaryngology, Head and Neck Surgery, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Paolo Giovanni CasaliDepartment of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Armelle DufresneMedical Oncology Department, Centre Leon Berard, Lyon, France.
Claudia SangalliDepartment of Radiation Therapy, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Christos GeorgalasDepartment of Otorhinolaryngology, Head and Neck Surgery, University of Nicosia Medical School, Nicosia, Cyprus.ORCID https://orcid.org/0000-0003-1158-020X
Ester OrlandiRadiation Oncology Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.
Peter-John WormaldDepartment of Otolaryngology, Head and Neck Surgery, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Philippe HermanOtorhinolaryngology and Skull Base Center, AP-HP, Hôpital Lariboisière, Université De Paris, Paris, France.
Ricardo CarrauDepartment of Otolaryngology, Head and Neck Surgery, The Ohio State University, Columbus, Ohio, USA.
Ehab Y HannaDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lisa LicitraDepartment of Oncology and Hematology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
Mario Turri-ZanoniDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, ASST Lariana, Como, Italy.ORCID https://orcid.org/0000-0002-3678-9088
Paolo BattagliaDivision of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, ASST Lariana, Como, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSinonasal sarcomas are exceedingly rare entities, constituting less than 7% of head and neck sarcomas. Their complex histology needs specialized treatment, which is often based on multimodal approaches including surgery, radiation therapy, and/or chemotherapy. This manuscript aims to gather expert opinions to establish common management principles for sinonasal sarcomas.

methodsThis international consensus followed a modified Delphi method in seven steps, including statements definition by the core group, expert panel recruitment, and a two-round survey. Sixty-two statements on sinonasal sarcoma management were developed. Experts from multiple continents participated, and results were anonymized and analyzed between March and May 2025.

resultsA total of 44 invited experts were recruited, 43.2% otorhinolaryngologists/head and neck surgeons, 31.8% medical oncologists, and 25% radiation oncologists. Participants varied in age and experience, representing Europe (70.5%), North America (18.2%), South America (6.8%), and Asia (4.5%). Among all histologies, biphenotypic sarcoma, chondrosarcoma, leiomyosarcoma, and myofibrosarcoma are principally treated with an upfront surgical management, differently from Ewing sarcoma and rhabdomyosarcoma in which chemotherapy, eventually associated with radiotherapy, is often chosen. In the remaining histologies (angiosarcoma, liposarcoma, malignant peripheral nerve sheath tumor [MPNST], osteosarcoma, and synovial sarcoma), a precise multimodal treatment is less standardized and needs to be discussed on a case-by-case basis.

conclusionSinonasal sarcomas require a histology-driven approach to determine upfront treatment, whether surgical, medical, or multimodal. Despite this structured strategy, prognosis remains highly variable across subtypes. Multidisciplinary evaluation and individualized management in referral centers are crucial to address the biological diversity and anatomical complexity of these rare malignancies.

Indexed as

Paranasal Sinus NeoplasmsSarcomaCombined Modality TherapyHumansangiosarcomabiphenotypic sinonasal sarcomachondrosarcomaEwing sarcomaleiomyosarcomamalignant peripheral nerve sheath tumorosteosarcomarhabdomyosarcomasinonasal sarcomassynovial sarcoma

Identifiers

PMID41025537
PMCPMC12761347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.